Introduction: Clinical trials have demonstrated the efficacy of all-oral direct-acting antiviral (DAA)
INTRODUCTION
Chronic hepatitis C (CHC) is a progressive liver disease caused by infection with the hepatitis C virus (HCV). CHC affects approximately 130-150 million people globally, and up to 500,000 people die each year from liver diseases associated with CHC [1] . In the United States (US), approximately 3 million individuals are infected with HCV. Approximately, 75% of these infections are attributed to HCV genotype 1 [2] . The first-generation direct-acting antivirals (DAAs) include the NS3/4A serine protease inhibitors telaprevir and boceprevir, and the NS5B ribonucleic acid (RNA) polymerase inhibitor sofosbuvir. Clinical trials demonstrated that use of these DAAs in combination with peginterferon and ribavirin was associated with sustained virologic response (SVR) in up to 75% (telaprevir and boceprevir) to 90% (sofosbuvir) of patients with HCV genotype 1 infection [3] . However, results of real-world studies of these regimens have been discordant with those of the clinical trials. For example, SVR rates in real-world studies of telaprevir have been reported at 44-52%, and at 72% for older sofosbuvir-based regimens [4] [5] [6] .
The second-generation DAA regimens paritaprevir/ritonavir/ombitasvir; dasabuvir (3D) and sofosbuvir/ledipasvir (SOF/LDV) were approved by the US Food and Drug Administration (FDA) for patients with HCV genotype 1. These all-oral regimens have been associated with improved efficacy, safety, tolerability, and shorter durations when compared to first-generation protease inhibitor regimens [3, 7] . Additionally, these newer regimens have been shown to be cost-effective across all fibrosis stages [8, 9] . [11] . SVR rates were examined using descriptive statistics, and differences in SVR rates between treatment groups were assessed using Fisher's exact tests. SVR rates were also assessed using multivariate logistic regression analysis, controlling for age group, sex, and 
RESULTS
A total of 55,871 patients in the database received a prescription for 3D (n = 2174) and/ or SOF/LDV (n = 53,697) during the study period ( Fig. 2 ). Of these, 169 were excluded because of a prescription for both DAAs, and 13 (3D) and 592 (SOF/LDV) were exclude for age \19 years of age. Of the remaining 54,928 patients, 18.5% (n = 369, 3D) and 18.2% Baseline characteristics of the patients in each treatment group were similar ( Table 1) . The majority (60%) of patients were male, and nearly half (49%) were aged 55-64 years. In addition, the majority (97%) of patients have not received HCV treatment in the year prior to 3D paritaprevir/ritonavir/ombitasvir; dasabuvir, SOF/LDV sofosbuvir/ledipasvir a Treatment history: in the 1 year prior to the start of 3D or SOF/LDV, any one of the following combinations: peginterferon plus ribavirin; telaprevir plus peginterferon plus ribavirin; boceprevir plus peginterferon plus ribavirin; sofosbuvir plus simeprevir with or without ribavirin; sofosbuvir plus ribavirin; sofosbuvir plus peginterferon plus ribavirin; simeprevir plus peginterferon plus ribavirin b Comorbidities were present in n = 611 (n = 11 3D; n = 600 SOF/LDV) of patients overall. Some patients had C1 comorbidity 108 days (3rd quartiles), for 3D and SOF/LDV, respectively (Fig. 3A) . Among 877 patients with a viral load assessment from 12 to 30 weeks following the EOT (n = 15 for 3D; n = 862 for SOF/LDV), the median time of assessment was approximately 15 weeks for patients in both groups (Fig. 3b) .
As illustrated in Fig. 4 , the majority of patients with a viral load assessment achieved SVR in each treatment group. When including latest viral load assessed within 4-30 weeks post-treatment, unadjusted SVR rates were 98% and 96% for patients who received 3D and SOF/LDV, respectively (Fig. 4 ). An ad hoc analysis of patients with a viral load assessment from 12 to 30 weeks post-treatment showed unadjusted SVR rates of 100% and 95% for 3D and SOF/LDV, respectively. The differences in SVR rates between treatment groups were not statistically significant (P = 1.0). Results of multivariate analyses controlling for age group, sex, and treatment history confirmed that SVR rates (parameter estimate -0.017, P = 0.5032) were not statistically significant for patients assessed from 4 to 30 weeks post-treatment (Table 2 ). However, ad hoc analysis of SVR from 12 to 30 weeks demonstrated that patients treated with SOF/ LDV were 8.4% less likely to achieve SVR than those treated with 3D (parameter estimate -0.084, P\0.0001). The unadjusted relative risk (RR) for achieving SVR in patients treated with SOF/LDV compared with 3D was 0.98%, 95% confidence interval (CI): 0.93-1.02. After adjusting for the baseline covariates, the RR was 0.98%, 95% CI: 0.94-1.03 (Table 3) .
DISCUSSION
Results from controlled clinical trials have suggested that the emergence of novel, all-oral DAA regimens holds the promise of achieving much higher rates of SVR among patients infected with HCV than was possible with previous treatments, with improved efficacy and tolerability, and reduced treatment duration [12] [13] [14] [15] [16] [17] [18] [19] . This is the first report of the effectiveness as measured by post-treatment SVR rates associated with both 3D and SOF/ LDV in a real-world setting. 12 were reported in a recent study of patients with HCV Fig. 4 Unadjusted SVR rates. 3D paritaprevir/ritonavir/ ombitasvir; dasabuvir, HCV hepatitis C virus, SOF/LDV sofosbuvir/ledipasvir, SVR sustained virologic response [21] . Therefore, for this study, the earliest time for assessment of SVR was 4 weeks following the EOT. To accommodate real-world variability in the timing of SVR assessment, this study included SVR rates ranging from 4 weeks to 30 weeks post-treatment. When multiple viral load results were available, the result closest to 30 weeks was used to reflect the real-world SVR of the new DAAs. However, since the AASLD/IDSA 2015 guidelines [11] recommend the SVR rate to be collected at 12 or more weeks after completing treatment, we also reported 12-to 30-week SVR rates. Due to the early view of this data, limiting the SVR to 12-30 weeks resulted in a small sample size; caution should be used in interpreting this result. These results were shown to be in concordance with the 4-to 30-week results.
In the 4-to 30-week cohort, the median time of viral load testing was approximately 3 weeks earlier for patients on 3D vs. those on SOF/LDV.
In contrast, the median time of testing in the 12-to 30-week cohort was similar (\1 week difference) for patients on both regimens. The differences in these times may be a reflection of the FDA approval dates and HCV treatment start dates: The later in the observation period a patient begins HCV treatment, the lower the probability they will be in the database long enough to have an assessment at 4 or 12 weeks post-treatment.
This study is the first to assess the real-world effectiveness of the new all-oral DAAs in the treatment of HCV. A particular strength of the study was its use of a large administrative claims database, which captured a large cross section of the US population. However, this study does have limitations that should be considered in the interpretation of these results. First, this is an early-view study; sample size was limited because the medications assessed have only been recently approved. In addition, only 27.3% (44/161) of patients had a recorded lab test during the study period, suggesting patients may have not had enough time in the study to measure an SVR. Genotype testing was limited due to the integration of the pharmacy and laboratory database, where approximately 18% of the patients in the pharmacy database were also in laboratory database. Therefore, the limited sample size precluded assessments of differences in patient subgroups of interest (e.g., HCV genotypes 1a vs. 1b, treatment-naïve vs.
experienced, treatment duration, HCV/HIV-1 coinfection, fibrosis stage and presence of cirrhosis, and other comorbidities such as renal insufficiency) and may limit the ability to minimize selection bias. Additional limitations are common to studies using 
